Signe Stensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/126150/publications.pdf

Version: 2024-02-01

		933447	1058476	
15	402	10	14	
papers	citations	h-index	g-index	
		2.5	110	
15	15	15	440	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.6	118
2	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61
3	Factors associated with typeâ€specific persistence of highâ€risk human papillomavirus infection: A populationâ€based study. International Journal of Cancer, 2016, 138, 361-368.	5.1	41
4	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	3.6	37
5	GIP and the gut-bone axis – Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	2.4	25
6	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	2.9	25
7	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21
8	GIP's involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	2.4	18
9	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	3.7	15
10	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp> (3â€30) <scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
11	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
12	Awareness of human papillomavirus after introduction of HPV vaccination: a large population-based survey of Scandinavian women. European Journal of Cancer Prevention, 2017, 26, 170-178.	1.3	8
13	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	4.4	5
14	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.6	3
15	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.6	1